E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Annual Aegis Virtual Conference
May 01, 2023 16:01 ET | electroCore, Inc.
ROCKAWAY, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
National Institutes of Health Awards Grant for Pivotal Clinical Trial of gammaCore™ (nVNS) in Patients with Opioid Use Disorders
April 26, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the National Institute on...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning
April 24, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the Air Force Research...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Announce First Quarter Financial Results on Wednesday, May 3
April 19, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
EC-Logo-2018_TM_CMYK.jpg
electroCore Provides Select First Quarter 2023 Financial Guidance
April 17, 2023 08:00 ET | electroCore, Inc.
Record revenue of approximately $2.8M expected for the three months ended March 31, 2023; 46% increase over first quarter of 2022 Revenue in first full quarter of Truvaga sales of approximately...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
April 12, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Remittance of Annual License Fee from Teijin for Certain Exclusive Rights in Japan
April 11, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Teijin...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa
April 06, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute
April 04, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury
March 23, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a paper...